Maravai LifeSciences Holdings Management
Management criteria checks 3/4
Maravai LifeSciences Holdings' CEO is Trey Martin, appointed in Jul 2023, has a tenure of 1.5 years. total yearly compensation is $2.30M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth €1.48M. The average tenure of the management team and the board of directors is 2.3 years and 4.2 years respectively.
Key information
Trey Martin
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 32.6% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.3yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$225m |
| Jun 30 2024 | n/a | n/a | -US$132m |
| Mar 31 2024 | n/a | n/a | -US$131m |
| Dec 31 2023 | US$2m | US$750k | -US$119m |
| Sep 30 2023 | n/a | n/a | US$25m |
| Jun 30 2023 | n/a | n/a | US$75m |
| Mar 31 2023 | n/a | n/a | US$153m |
| Dec 31 2022 | US$15m | US$660k | US$220m |
Compensation vs Market: Trey's total compensation ($USD2.30M) is above average for companies of similar size in the German market ($USD1.55M).
Compensation vs Earnings: Trey's compensation has been consistent with company performance over the past year.
CEO
Trey Martin (49 yo)
1.5yrs
Tenure
US$2,301,864
Compensation
Mr. William E. Martin, III, also known as Trey, is Director of Maravai LifeSciences Holdings, Inc. from July 31, 2024. He was President of Biologics Safety Testing of Maravai LifeSciences Holdings, Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.5yrs | US$2.30m | 0.11% € 1.5m | |
| Executive VP & CFO | 7.7yrs | US$2.79m | 0.022% € 299.7k | |
| Executive VP & Chief Administrative Officer | 2.6yrs | US$2.83m | 0.039% € 532.9k | |
| Executive VP & GM of Cygnus Technologies | 7.3yrs | US$2.26m | 0.020% € 265.4k | |
| President of Nucleic Acid Production | 1.8yrs | US$2.99m | 0.024% € 321.7k | |
| Chairman of the Board | less than a year | no data | no data | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Executive VP | 4.2yrs | US$701.40k | 0.018% € 246.9k | |
| Executive VP & Chief Commercial Officer | 1.9yrs | no data | 0.021% € 282.5k | |
| Chief Innovation Officer | 1.9yrs | no data | no data |
2.3yrs
Average Tenure
55yo
Average Age
Experienced Management: MAR's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$2.30m | 0.11% € 1.5m | |
| Chairman of the Board | less than a year | no data | no data | |
| Independent Director | 1.5yrs | US$435.03k | 0.020% € 267.7k | |
| Non-Independent Director | 4.2yrs | US$370.48k | 0.0030% € 40.6k | |
| Non-Independent Director | 4.2yrs | US$367.98k | 0.0030% € 40.6k | |
| Independent Director | 4.2yrs | US$360.48k | 0.039% € 524.6k | |
| Independent Director | 4.2yrs | US$395.48k | 0.025% € 343.8k | |
| Non-Independent Director | 4.2yrs | US$360.48k | 0.0030% € 40.6k | |
| Non-Independent Director | 4.2yrs | US$360.48k | 0.0030% € 40.6k | |
| Independent Director | 4.2yrs | US$367.98k | 0.015% € 198.2k | |
| Independent Director | 4.2yrs | US$387.98k | 0.047% € 629.3k |
4.2yrs
Average Tenure
59yo
Average Age
Experienced Board: MAR's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 10:43 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Maravai LifeSciences Holdings, Inc. is covered by 17 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |